On January 8, 2024 Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, reported that it has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD) to analyze therapeutic response and provide molecular insights for AFT’s interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC) (Press release, Quest Diagnostics, JAN 8, 2024, View Source [SID1234639102]). The AFT-57 clinical study is supported by Genentech, a member of the Roche Group, and will explore the efficacy and safety of an anti-PD-L1 atezolizumab (Tecentriq) with or without tiragolumab (anti-TIGIT) in conjunction with chemoradiotherapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)
"This research collaboration with AFT is a great opportunity to further explore the benefits of using highly sensitive and specific ctDNA analysis as a means to evaluate the efficacy of novel therapeutic approaches," said Dan Edelstein, Vice President and General Manager of Haystack Oncology. "Haystack MRD was purpose-built to detect ctDNA with unparalleled sensitivity, making it well-positioned to support the innovation of new treatment regimens."
"AFT is excited to work with Haystack Oncology to investigate promising new immunotherapy-based treatments in nationwide randomized cancer clinical trials," said David Kozono, MD, PhD, AFT Executive Officer and Alliance Immuno-Oncology Committee Co-Chair. "The new MRD technology, in conjunction with these novel therapies, offers a unique opportunity to significantly impact the lives of patients with inoperable locally advanced non-small cell lung cancer."